Erin A. KimbrelBA, PhD
Dr. Erin A. Kimbrel is the Director of Translational Research at Ocata Therapeutics. She has over 12 years experience in the stem cell field, the last 6 of which have been in the biotechnology sector where she has been working on the development of human pluripotent stem cell-derived cell-based therapies. Her current focus involves the integration of preclinical research, product development, manufacturing, and business strategy for the development of PSC-based products.
She is a co-author on nearly 20 publications and an inventor on numerous patents. Dr. Kimbrel is a former Fulbright scholar and member of Phi Beta Kappa, receiving her B.A. Magna Cum Laude, from Holy Cross College in Worcester, MA and her Ph.D. in Pharmacology and Cancer Biology from Duke University. Her post doctoral studies were conducted at Dana-Farber Cancer Institute/Harvard Medical School, where her research focused on transcriptional regulation of hematopoietic differentiation and stem cell fate decisions.